J. Moore

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

E. Winer, G. Hortobagyi, D. Booser, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

G. Hortobagyi, G. Gladish, D. Booser, 2012, Cancer.

Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

E. Winer, G. Hortobagyi, D. Booser, 2010 .

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

N. Ibrahim, D. Booser, D. Tripathy, 2023, Cancer.